CELC
NASDAQ HealthcareCelcuity Inc. - Common Stock
Biotechnology
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
�� 市场数据
| 价格 | $122.46 |
|---|---|
| 成交量 | 471,814 |
| 市值 | 5.92B |
| 贝塔系数 | 0.420 |
| RSI（14日） | 70.5 超买 |
| 200日均线 | $79.44 |
| 50日均线 | $111.62 |
| 52周最高 | $127.34 |
| 52周最低 | $9.51 |
| Forward P/E | -111.33 |
| Price / Book | 58.76 |
🎯 投资策略评分
CELC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (63/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (11/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 CELC in your text
粘贴任何文章、记录或帖子 — 工具将提取 CELC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.